News

THE BOD APPROVES THE INTERIM MANAGEMENT REPORT AS OF MARCH 31ST 2026

SHAREHOLDERS’ MEETING OF 04/27/2026 – SUMMARY REPORT OF VOTING RESULTS

RESOLUTIONS OF THE ORDINARY SHAREHOLDERS’ MEETING AND OF THE BOD OF APRIL 27, 2026

Pharmanutra World Partner Convention 2026: shaping our future together

PHARMANUTRA S.P.A. ALONGSIDE “AF CORSE,” FERRARI HYPERCAR’S RACING PARTNER

FILING OF DOCUMENTS FOR THE SHAREHOLDERS’ MEETING

BOD APPROVES THE DRAFT FINANCIAL STATEMENTS AND THE CONSOLIDATED FINANCIAL STATEMENTS AS AT 31.12.2025

Pharmanutra obtains FDA registration for its Pisa manufacturing facility

DISTRIBUTION OF SIDERAL® PRODUCTS IN FRANCE AND SWITZERLAND

APPROVAL OF THE BOARD OF DIRECTORS GUIDELINES AND APPOINTMENT OF THE INVESTOR RELATIONS DIRECTOR

PHARMANUTRA S.P.A. OBTAINS ISO 13485 CERTIFICATION

Pharmanutra strengthens its commitment to elite sport: agreement with Lorenzo Musetti, new Cetilar® Nutrition Ambassador

SOLID DOUBLE-DIGIT REVENUE GROWTH IN 2025 DRIVEN BY STRONG CONTRIBUTION FROM INTERNATIONAL MARKETS AND NEW BUSINESS UNITS

PUBLICATION OF THE 2026 CORPORATE EVENTS CALENDAR

Pharmanutra accelerates international expansion in the Far East through the Alibaba ecosystem

Cetilar® Nutrition confirmed as Official Nutrition Partner of the 2026 Giro d’Italia

PHARMANUTRA S.P.A. LISTED AMONG THE WORLD’S BEST COMPANIES FOR SUSTAINABLE GROWTH BY “TIME” MAGAZINE

BOARD OF DIRECTORS APPROVES THE INTERIM MANANGEMENT REPORT AS OF SEPTEMBER 30, 2025

MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUERS SECURITIES

Pharmanutra awards ten graduation prizes to young graduates of the University of Parma